These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 27220339)

  • 1. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
    Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant
    Rubic Z; Soprek S; Jelic M; Novak A; Goic-Barisic I; Radic M; Tambic-Andrasevic A; Tonkic M
    Microb Drug Resist; 2021 Feb; 27(2):162-169. PubMed ID: 32429775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of SXT/R391-like integrative and conjugative elements carrying blaCMY-2 in Proteus mirabilis.
    Mata C; Navarro F; Miró E; Walsh TR; Mirelis B; Toleman M
    J Antimicrob Chemother; 2011 Oct; 66(10):2266-70. PubMed ID: 21752830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
    J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
    Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
    Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
    Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
    J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristic of fluoroquinolone resistant clinical isolates of K. pneumoniae, P. mirabilis and E. coli producing ESBL and AmpC beta-lactamases].
    Rzeczkowska M; Piekarska K; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(4):285-95. PubMed ID: 23484420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired AmpC type beta-lactamases: an emerging problem in Italian long-term care and rehabilitation facilities.
    Migliavacca R; Nucleo E; D'Andrea MM; Spalla M; Giani T; Pagani L
    New Microbiol; 2007 Jul; 30(3):295-8. PubMed ID: 17802913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
    Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B
    Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four variants of the Citrobacter freundii AmpC-Type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland.
    Literacka E; Empel J; Baraniak A; Sadowy E; Hryniewicz W; Gniadkowski M
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4136-43. PubMed ID: 15504832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
    Khan MK; Thukral SS; Gaind R
    Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.
    Ibrahimagić A; Bedenić B; Kamberović F; Uzunović S
    J Infect Chemother; 2015 May; 21(5):363-9. PubMed ID: 25638292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy.
    D'Andrea MM; Nucleo E; Luzzaro F; Giani T; Migliavacca R; Vailati F; Kroumova V; Pagani L; Rossolini GM
    Antimicrob Agents Chemother; 2006 Feb; 50(2):618-24. PubMed ID: 16436718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
    J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissemination of a Multidrug-Resistant VIM-1- and CMY-99-Producing Proteus mirabilis Clone in Bulgaria.
    Markovska R; Schneider I; Keuleyan E; Ivanova D; Lesseva M; Stoeva T; Sredkova M; Bauernfeind A; Mitov I
    Microb Drug Resist; 2017 Apr; 23(3):345-350. PubMed ID: 27341161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CMY-2-type plasmid-mediated AmpC ß-lactamases emerging in Tucumán, Argentina].
    Jure MA; Presti C; Cudmani NM; Grellet LM; López C; Musa EH; Aulet OC; Nieto C; Saavedra L; de Castillo MC
    Rev Argent Microbiol; 2011; 43(1):24-7. PubMed ID: 21491062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital.
    Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH
    APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway.
    Naseer U; Haldorsen B; Simonsen GS; Sundsfjord A
    Clin Microbiol Infect; 2010 Feb; 16(2):171-8. PubMed ID: 19548922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.